Astrazeneca Ab

Aaron Rigby

Brian Springthorpe

Hitesh Jayantilal Sanganee

Louise Lawrence

Roger Victor Bonnert

Timothy Jon Luker

Mark Furber

Lilian Alcaraz

Anil Patel

Christopher Luckhurst

Peter Cage

Elizabeth Kinchin

The present invention relates to (2S)-2-({3'-Chloro-4&#x2032;-[(2,2-dimethylpyrrolidin-1-yl) carbonyl]-5-fluorobiphenyl-2-yl}oxy)propanoic acid and (2R)-2-({3&#x2032;-chloro-4&#x2032;-[(2,2-dimethylpyrrolidin-1-yl) carbonyl]-5-fluorobiphenyl-2-yl}oxy)propanoic acid of formula (I), and crystalline forms and pharmaceutically acceptable salts thereof useful as pharmaceuticals. 

Bi-aryl amide compounds as CRTh2 receptor modulators

Compounds of formula (I): are modulators of chemokine (for example CCR3) activity (for use in, for example, treating asthma).

Piperidines as chemokine modulators (CCR)

The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

Chemical compounds

The present invention provides a compound of a formula (I):wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

Bipiperidine compounds

Bipiperidine derivatives as modulators of CCR3 activity and as H1 antagonists

Growing community of inventors

Loughborough, United Kingdom

Aaron Rigby